MedTrace Logo

Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases

NCT01248429 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2026-03-16

No results posted yet for this study

Summary

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Conditions

Interventions

BIOLOGICAL

CPK dosage

CPK dosage during a blood sample realized at least one week after the begining of the treatment

OTHER

Clinical exam

Examination of the patient for myalgia, cramps, medical history and concomitant medication

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Antoine ADENIS, MD, PhD · Centre Oscar Lambret

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-12-31
Completion
2013-01-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248429 on ClinicalTrials.gov